-
to validate single cell RNA sequencing and proteomic results. Serological study on human cohort will be assessed ELISA and Luminex-based method to determine the antibody/inflammatory response and flesh out
-
of neurodegenerative diseases, with emphasis on amyotrophic lateral sclerosis (ALS). We are particularly interested in understanding how different neurons modulate their epigenome, transcriptome, and proteome in
-
the models on high-throughput datasets, including metabolomics, proteomics, and transcriptomics and use them to identify systems-level mechanisms in cancer to enhance treatment efficacy by uncovering
-
datasets, including metabolomics, proteomics, and transcriptomics and use them to identify systems-level mechanisms in cancer to enhance treatment efficacy by uncovering new drug targets, biomarkers, and
-
characterization at the mRNA, miRNA, proteome and metabolome level from multiple lung compartments to construct a model of disease. The work will be conducted on one or several unique clinical cohorts designed
-
the responsible experimentalist. Large-scale planning and handling of clinical samples (hundreds of clinical samples each day) and their organization into plates for proteomic analysis. PBMC prep, plasma prep, and